04:08 AM EDT, 08/26/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday the European Commission has approved Yeytuo, its twice-yearly injectable HIV-1 prevention drug, for certain adults and adolescents at higher risk of HIV-1 infection.

The company said the drug received an accelerated review due to its public health importance, following a positive recommendation from a European Medicines Agency committee in July.

The approval also grants Yeytuo one extra year of market protection in the EU, the company said.

The authorization of Yeytuo was backed by efficacy and safety data from two phase 3 trials, Gilead said.